Mesh Bio becomes the first Asian start-up to join Startup Creasphere, the Digital Health Innovation Program, established by Roche, Sanofi CHC and Plug and Play

Mesh Bio Co-Founder & CTO, Arsen Batagov, (left) and Co-Founder & CEO, Andrew Wu (right).

Mesh Bio, a Singapore-based predictive analytics digital health startup for diagnosis and management of chronic diseases, has announced today their participation in the upcoming Startup Creasphere Batch 3 accelerator program, an international collaboration set to pilot Mesh Bio’s digital solutions. 

Startup Creasphere is the first health innovation focused accelerator in Munich, Germany. The program selects and empowers innovative healthtech companies that hold immense potential to transform the current global healthcare ecosystem. Powered by Plug and Play, a leading global innovation platform and venture fund from Silicon Valley, Roche, a global pioneer in pharmaceuticals and diagnostics, and Sanofi CHC, an international leader in consumer healthcare and pharmaceuticals, Startup Creasphere provides state-of-the-art infrastructure, bespoke programs and global networks to accelerate the success of promising health tech startups from around the world.

From hundreds of global applicants, Mesh Bio represents the only Asian company amongst the startups selected for this prestigious program. Mesh Bio’s participation in Startup Creasphere, puts Singapore on the global map in the digital health technology space. This recognition reinforces the government’s efforts to make Singapore a gateway to Southeast Asia’s digital healthcare market.   

“Roche Diagnostics is a global leader in clinical diagnostics. We are privileged to be invited to participate in the Startup Creasphere digital health acceleration program. This program allows Mesh Bio to engage early with global healthcare leaders. It also gives us the opportunity to harness global knowledge and expertise to fine-tune our solutions for greater healthcare impact in chronic disease management,” said Dr. Andrew Wu, co-founder and CEO of Mesh Bio. 

Digital health has the potential to transform healthcare delivery for patients around the world. Asia is an important growth area, and effective chronic disease diagnosis and management is a key challenge for healthcare delivery. Startups with deep regional understanding, such as Mesh Bio, enables usage of innovative diagnostic tests to be tailored to the needs of providers and patients.

About Mesh Bio
Mesh Bio is addressing the growing global burden of chronic diseases due to an aging population, and a shortage of primary care expertise. Mesh Bio provides advanced predictive analytics clinical software solutions for personalised risk assessment and health management. This enables early detection of the dysfunctions, easing the complexity of healthcare delivery – a challenge faced by patients, healthcare providers and payors.
Mesh Bio was founded by an experienced team of healthcare professionals with deep expertise in diagnostics, systems biology and healthcare management.

About Startup Creasphere 
Startup Creasphere is an innovation platform at the heart of Europe, where forward-thinking corporations and disruptive startups can meet and create meaningful engagements. It creates an environment within our global digital health ecosystem to pilot solutions and services, drive investments, learn and share experiences and facilitate international expansion.

Media inquiries contact:
Scarlett Chong scarlett@meshbio.com

Leave a Reply